Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

BackgroundArginase-1-producing cells inhibit T cell-mediated anti-tumor responses by reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of arginase-1-expressing cells could potentially restore L-arginine levels and improve anti-tumor responses. The activation of...

Full description

Bibliographic Details
Main Authors: Cathrine Lund Lorentzen, Evelina Martinenaite, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Sofie Kirial Mørk, Ayako Wakatsuki Pedersen, Eva Ehrnrooth, Mads Hald Andersen, Inge Marie Svane
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
arginase-1
peptide
vaccination
solid tumors
first-in-human
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1023023/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1023023/full

Similar Items